STAT+: Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles
Medicare confirmed this week that it will cover Novo Nordisk’s obesity drug Wegovy if prescribed…
Category: Medicine
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, FDA syringe warnings, and more
And so, another working week will soon draw to a close. Not a moment too…
EU adviser says Illumina merger was not problematic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Drug development was once a marathon. New tools and timelines are turning it into a sprint
Drug development is more of a sprint than a marathon these days, thanks to more…
Opinion: STAT+: Medical devices makers are trying to take a page from Uber’s playbook
In a recent survey of U.S. companies, medical device makers reported spending $31 million on…
Male birth control research wins audience over at STAT Madness event
What happens when too many excellent, pioneering researchers enter a room? A little madness. That’s…
STAT+: Hospitals turn to sports performance centers to offer athletes elite care — for the right price
FOXBOROUGH, Mass. — Jodi Cullity calls herself a pickleball fanatic. The 29-year-old is the founding…
Listen: Live! From the STAT Breakthrough Summit East
Is there a cure for allergies? Has the FDA become too flexible? And which drugs…
Top U.S. addiction researcher calls GLP-1 data for addiction ‘very, very exciting’
Early data regarding the use of GLP-1 medications like Ozempic and Wegovy to treat addiction…
STAT+: Ibogaine, the psychedelic, unlikely to receive approval as opioid treatment, says top addiction researcher
The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction,…
STAT+: Regeneron’s plot to ‘cure’ allergies
George Yancopoulos is in touch with his teenage self. After 35 years as head scientist…
Getting CRISPR treatments to patients remains a major challenge. Could lab-developed tests help?
CRISPR is no longer a promising but unproven technology — it is a reality. But…
STAT+: Feng Zhang suggests Editas didn’t move quickly enough to find product targets
When the first biotech companies emerged to capitalize on the revolutionary genome-editing technology CRISPR, Editas…
STAT+: Digital tools for diabetes management did not deliver benefits that justify cost, new report finds
The last decade has seen billions of dollars flow into digital health companies that promise…
STAT+: Gene-edited pig kidney transplanted into a living patient for the first time
In a new test of xenotransplantation, a medical team at Massachusetts General Hospital announced Thursday…
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, GSK asthma inhalers, and more
Top of the morning to you, and a fine one it is. Although quite chilly…
BioNTech is having its Pfizer moment
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Prometheus team launches new startup with $400 million to tackle immune-driven disorders
What happens after you close a nearly $11 billion acquisition? Well, for Prometheus Therapeutics’ former…
STAT+: Pharma companies and their allies seek to exempt orphan drugs from state pricing limits
As more states create dedicated boards to cap the costs of medicines, some drugmakers and…
STAT+: U.K. health officials and researchers try to carve a path for more individualized genetic treatments
LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies…
Opinion: The influential adverse childhood experiences questionnaire should ask about gun violence
The adverse childhood experience (ACE) questionnaire has become a critical part of public health. It…
STAT+: A preview of Intra-Cellular Therapies’ depression drug, and sizing up the MASH opportunity
I am one week away from the launch of my weekly email newsletter! It’s called…
Overdose deaths hit another record but show signs of leveling off
The U.S. recorded 107,941 drug overdose deaths in 2022, according to a new federal report…
STAT+: Medicare expected to negotiate obesity drug prices soon, new analysis predicts
WASHINGTON — Medicare will likely choose the obesity drug semaglutide for price negotiation “within the…
The U.S. banned asbestos, but its health impact will still be felt for decades
A new rule announced by the Environmental Protection Agency this week puts an end to…
STAT+: Pharmalittle: We’re reading about Europe’s pharma reform, weight-loss meds, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
.jpg)
Novo is building a really big computer
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: J&J sues former employee for allegedly taking thousands of documents to a new job at Pfizer
Johnson & Johnson has accused a long-standing employee of taking thousands of confidential files about…
STAT+: Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO
Robert Ross had thought he would take more time off after his previous company, Surface…
STAT+: New gene therapy, to be priced at $4.25 million, has already transformed children’s lives
Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the…
Opinion: Sabbaticals for nurses could help fight worker shortages and burnout
A new study suggests that the nursing shortage is easing, but that doesn’t mean the health care…
Fetal tissue research gains in importance as roadblocks multiply
Scientists at the University of Wisconsin-Madison have spent years trying to unravel the details of…
STAT+: A scientific mystery highlights the blind spots in genomics databases
The two patients had both died young from heart problems. When researchers looked at their…
STAT+: UnitedHealth appears to be upping loan offers to providers, after Change cyberattack
UnitedHealth Group appears to be offering some providers more substantial loans in the wake of…
A study says intermittent fasting is making people drop dead. Oh, come on
The news is everywhere in my social news feeds this morning: A popular fad diet…
STAT+: In small study, baby aspirin cuts fat buildup in liver disease patients
Low-dose aspirin led to a reduction in liver fat among patients with metabolic-associated liver disease,…
Wegovy and Zepbound get primetime treatment
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: Pharmalittle: We’re reading about an AstraZeneca deal, a WHO pandemic pact, and more
Rise and shine, everyone, another busy day is on the way. Already, the official mascots…
STAT+: Q&A: Mark Parrino says it’s time to ‘completely re-examine’ methadone treatment for opioid addiction
Nobody has made more of an impact on methadone treatment than Mark Parrino. For decades,…
STAT+: The methadone clinic monopoly: Opioid treatment chains backed by private equity are fighting calls for reform
Private equity firms have acquired stakes in nearly one-third of all methadone clinics in recent…
Opinion: The evidence is clear: A liquid-only diet before a colonoscopy is unnecessary
Since colorectal cancer is on the rise in people younger than age 50, national guidelines…
STAT+: As targeted radiation field heats up, AstraZeneca to pick up Fusion Pharmaceuticals in $2 billion deal
LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more…
Supreme Court questions restricting government efforts to limit Covid-19 misinformation
WASHINGTON — Most of the Supreme Court’s justices on Monday seemed to question states’ arguments that…
STAT+: FDA approves first gene therapy for a fatal neuron disease in children
The Food and Drug Administration on Tuesday approved a gene therapy for metachromatic leukodystrophy, a…
EPA bans asbestos, a deadly carcinogen still in use decades after partial ban
WASHINGTON — The Environmental Protection Agency on Monday announced a comprehensive ban on asbestos, a…
Contineum Therapeutics files for IPO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: I was wrong about Geron’s blood cancer drug. Now, is it a takeover target?
I was wrong about Geron. For years, I’ve believed — and declared publicly — that…
STAT+: Pharmalittle: We’re reading about CAR-T drugs for myeloma, CVS rebate credits, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
The harms of adverse childhood experiences are well-known. But positive experiences can affect future health, too
I was recently working with a young mother who struggled with depression and anxiety in…
STAT+: As AI marches into medicine, investors eye security, privacy startups
Investors are starting to back startups that offer privacy and security services to bolster health…